Females Show Better Response to CRT in Esophageal Cancer

This article originally appeared here.
Share this content:
Females Show Better Response to CRT in Esophageal Cancer
Females Show Better Response to CRT in Esophageal Cancer

TUESDAY, Aug. 22, 2017 (HealthDay News) -- For patients with locally advanced esophageal carcinoma who received neoadjuvant chemoradiotherapy (nCRT), female sex is associated with increased likelihood of achieving a complete or nearly complete pathologic response, according to a study published online Aug. 22 in the Annals of Thoracic Surgery.

Phillip G. Rowse, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues examined the impact of sex on response to nCRT, tumor recurrence, and survival. One hundred forty-five female patients who received nCRT followed by esophagogastrectomy at three affiliated centers were compared with 221 control male patients.

The researchers found that, compared with men, women were more likely to attain a complete pathologic response or a nearly complete pathologic response to induction therapy (58 versus 47 percent; P = 0.034). Men had a significantly increased risk of recurrence (hazard ratio, 1.80; 95 percent confidence interval, 1.15 to 2.68; P = 0.008). No sex correlation was seen with the risk of death (P = 0.538). A partial responder was three times more likely to have recurrence compared with a complete or nearly complete responder, regardless of sex (hazard ratio, 2.96; 95 percent confidence interval, 1.98 to 4.43; P < 0.001), and was also significantly more likely to die (hazard ratio, 2.56; 95 percent confidence interval, 1.88 to 3.48; P < 0.001).

"Future efforts should be directed at understanding determinants of this sex disparity," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »